Quale sarebbe il prezzo per Intercept Pharmaceuticals, Inc. (ICPT)

Il prezzo per Intercept Pharmaceuticals, Inc. (ICPT) è $19.00

Qual è la capitalizzazione di mercato per Intercept Pharmaceuticals, Inc. (ICPT)

La capitalizzazione di mercato per Intercept Pharmaceuticals, Inc. (ICPT) è $629.64M

Intercept Pharmaceuticals, Inc. (ICPT) Frazionamenti Azionari

Intercept Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the advancement and market launch of therapies designed to treat progressive, non-viral liver conditions. Its operational reach spans the United States, Europe, and Canada. The company currently markets Ocaliva, a medication functioning as a farnesoid X receptor (FXR) agonist. This drug is approved for the treatment of primary biliary cholangitis (PBC) in adults, specifically when administered alongside ursodeoxycholic acid. Beyond its existing approved indications, Intercept is actively investigating Ocaliva's potential for additional uses, notably including nonalcoholic steatohepatitis (NASH). Concurrently, it is progressing other drug candidates through various clinical and preclinical stages of development. In a collaborative effort, the company holds a licensing agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. Intercept distributes its products through a dual approach, utilizing both its proprietary commercial organization and a network of external third-party distributors. The company was founded in 2002 and is headquartered in New York, New York.